As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a ...

Fintel reports that on November 4, 2024, Oppenheimer downgraded their outlook for ESSA Pharma (NasdaqCM:EPIX) from Outperform ...

Fintel reports that on November 1, 2024, Jones Trading downgraded their outlook for ESSA Pharma (NasdaqCM:EPIX) from Buy to ...

US clinical-stage firm ESSA Pharma has made the decision to terminate the Phase II clinical trial evaluating in a 2:1 ...

ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over ...

Piper Sandler analyst Joseph Catanzaro downgraded the rating on ESSA Pharma (EPIX – Research Report) to a Hold today, setting a price ...

The company’s fifty day simple moving average is $5.59 and its two-hundred day simple moving average is $5.55. ESSA Pharma has a 52 week low of $1.40 and a 52 week high of $11.67. The stock has a ...

ESSA Pharma (EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enz ...

In a report released on November 1, Maury Raycroft from Jefferies downgraded ESSA Pharma (EPIX – Research Report) to a Hold, with a price ...

Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, ...